SEC Company Response from Applied Therapeutics, Inc. (APLT) (CIK 0001697532) — Jan 21, 2020
Applied Therapeutics, Inc. (APLT) (CIK 0001697532)
Date: Jan. 21, 2020 · CIK: 0001697532 · Accession: 0001104659-20-005586
AI Filing Summary & Sentiment
File numbers found in text: 333-235988
Letter
Goldman Sachs & Co. LLC
Cowen and Company, LLC
UBS Securities LLC
As representatives of the
several underwriters listed
in Schedule I of the Underwriting Agreement
c/o Goldman Sachs & Co. LLC
200 West Street
New York, New York 10282
c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022
c/o UBS Securities LLC 1285 Avenue of the Americas New York, New York 10019
January 21, 2020
VIA EDGAR
Jeffrey Gabor
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RE: Applied Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-235988)
Request for Acceleration of Effective Date
Mr. Gabor:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Applied Therapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:30 p.m., Eastern Time, on January 23, 2020, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Skadden, Arps, Slate, Meagher & Flom LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably
anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
GOLDMAN SACHS & CO. LLC
Show Raw Text
CORRESP 1 filename1.htm Goldman Sachs & Co. LLC Cowen and Company, LLC UBS Securities LLC As representatives of the several underwriters listed in Schedule I of the Underwriting Agreement c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o UBS Securities LLC 1285 Avenue of the Americas New York, New York 10019 January 21, 2020 VIA EDGAR Jeffrey Gabor Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Applied Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-235988) Request for Acceleration of Effective Date Mr. Gabor: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Applied Therapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:30 p.m., Eastern Time, on January 23, 2020, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Skadden, Arps, Slate, Meagher & Flom LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, GOLDMAN SACHS & CO. LLC COWEN AND COMPANY, LLC UBS SECURITIES LLC As representatives of the several underwriters listed in Schedule I to the Underwriting Agreement GOLDMAN SACHS & CO. LLC By: /s/ Kristen Grippi Name: Kristen Grippi Title: Managing Director COWEN AND COMPANY, LLC By: /s/ Bill Follis Name: Bill Follis Title: Managing Director UBS SECURITIES LLC By: /s/ James Stahlke Name: James Stahlke Title: Associate Director By: /s/ Robin Tang Name: Robin Tang Title: Director [Signature Page to Underwriters’ Acceleration Request]